Looking for a Mounjaro contact number? Here's who actually helps

When you want to contact Eli Lilly about Mounjaro

Eli Lilly manufactures Mounjaro and maintains a UK medical information service. Their number, published on the official Lilly UK website (lilly.com/uk), is primarily designed for healthcare professionals, GPs, pharmacists and nurses who need detailed clinical or prescribing information. If you are a patient, Lilly's team will typically direct you back to whoever prescribed your treatment, because they cannot safely assess your personal medical situation over the phone.

That is not a bureaucratic brush-off. It reflects how prescription medicines are regulated in the UK. A manufacturer's medical affairs team can explain what a medicine contains and how it behaves generally (the kind of detail you can also find in the full ingredient breakdown for Mounjaro or in the Mounjaro SmPC on the electronic Medicines Compendium) but they cannot and should not advise on your dose, your side effects, or your eligibility for continued treatment.

So Lilly's line is worth knowing. It is rarely the fastest route to a practical answer for most patients. Keep reading to find who is.

Your prescribing pharmacist or clinic is the contact that matters most

If you are taking Mounjaro through a regulated private pharmacy, the prescriber who approved your treatment is the right person to reach whenever a clinical question comes up. That covers things like: a side effect that is not settling, uncertainty about what to do if a pen is damaged, questions about your next dose review, or anything that the patient information leaflet does not resolve for your specific situation.

At nume, our prescribers are GPhC-registered Independent Prescribers who review every consultation personally. Our aftercare team is available seven days a week. You can reach us directly through our contact page, and the same clinical oversight that approved your treatment remains accessible throughout it, no chasing a generic helpline.

A question our prescribers hear most weeks: "I can't find anyone to ask about my injection, who do I call?" The answer should always be your prescribing team first. If you are considering starting treatment and want to understand the process, our frequently asked questions cover a lot of common ground.

Reporting side effects and suspect products: the MHRA routes

Some contact needs sit outside your prescribing team entirely. If you experience a suspected side effect from Mounjaro (whether mild or serious) you can report it yourself via the MHRA's Yellow Card scheme. This is open to patients, carers and family members, not just clinicians. Reporting matters: it is how regulators build the real-world safety picture for newer medicines like tirzepatide, which carries a Black Triangle (▼) status indicating it is under additional MHRA monitoring.

If you have doubts about the authenticity of a pen (for example, if the packaging looks unusual or it was supplied without a valid prescription from a verifiable pharmacy) the MHRA Yellow Card site also handles reports of suspect medicines and illegal sellers. Do not use the pen. Contact the MHRA and your prescriber. You can also check the serial number verification process for Mounjaro pens as a first step.

For a broader picture of tirzepatide, including its CAS number and the chemical identity details behind it, how it works, and the clinical trial evidence, the tirzepatide overview on our site pulls together the key facts in one place.

Navigating contact when you don't have a GP or are changing provider

Some people reach the "who do I call?" question from a specific position: they are between providers, they have moved, or they have been taking Mounjaro privately and are unsure whether their GP needs to be involved. Taking Mounjaro without regular GP contact is a situation our prescribers see regularly and is worth understanding clearly.

In brief: UK guidance encourages GP notification whenever a patient starts a new treatment, including through a private route. At nume, we follow GPhC guidance on this. But not having a GP does not automatically block access to private treatment, clinical assessment still happens, and a prescriber still takes responsibility for your care.

If you are moving from another provider and want to continue treatment, the transfer process involves your prescriber reviewing your history and current dose. You can explore what that looks like through our Mounjaro treatment page, and if you are ready to begin, our weight-loss treatment consultation is the practical starting point. For a broader sense of how Mounjaro sits within private weight management, the weight-loss overview gives useful context before you commit to a specific path.

One concrete note: if you do start treatment through nume and your application is approved, your pen arrives from our GPhC-registered pharmacy the next working day via DPD, tracked, in plain unbranded packaging. The tracking notification lands on your phone, and the pen itself is sealed in tamper-evident packaging as it left our dispensary. That is worth knowing if you've been anxious about the process.